Equities

Arvinas Inc

ARVN:NSQ

Arvinas Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)26.31
  • Today's Change-1.73 / -6.17%
  • Shares traded846.86k
  • 1 Year change+75.52%
  • Beta1.8460
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,2611,2051,503
Total Receivables, Net7.208.0026
Total Inventory------
Prepaid expenses6.502120
Other current assets, total5.505.504.50
Total current assets1,2801,2401,553
Property, plant & equipment, net141817
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets101113
Total assets1,3051,2691,582
LIABILITIES
Accounts payable185.7031
Accrued expenses766124
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total164229206
Total current liabilities257295262
Total long term debt0.801.001.00
Total debt0.801.001.00
Deferred income tax------
Minority interest------
Other liabilities, total387408537
Total liabilities645704800
SHAREHOLDERS EQUITY
Common stock0.100.100
Additional paid-in capital1,9961,5491,469
Retained earnings (accumulated deficit)(1333)(965)(683)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.1)(19)(4.6)
Total equity660565782
Total liabilities & shareholders' equity1,3051,2691,582
Total common shares outstanding685353
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.